A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia

Journal of Clinical Neuroscience

Volumn 17, Issue 6, 2010, Pages 685-693

  Yuan, Z H ^a   Jiang, J K ^a   Huang, W D ^a   Pan, J ^a   Zhu, J Y ^a   Wang, J Z ^a  

^a First Affiliated Hospital   (China)

Author keywords

Intracerebral hemorrhage; Meta analysis; Randomized controlled trial; Recombinant activated factor VII; Thromboembolic adverse events

Indexed keywords

PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ACUTE DISEASE; ARTERY THROMBOSIS; BRAIN HEMORRHAGE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FUNCTIONAL ASSESSMENT; GLASGOW COMA SCALE; HEMATOMA; HUMAN; LOW DRUG DOSE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

ACUTE DISEASE; ANIMALS; CEREBRAL HEMORRHAGE; FACTOR VIIA; GLASGOW COMA SCALE; HEMOSTATICS; HUMANS; META-ANALYSIS AS TOPIC; RECOMBINANT PROTEINS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77953131353     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.11.020     Document Type: Review

References (36)

1. Broderick J.P., Brott T.G., Duldner J.E., et al. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 24 (1993) 987-993
2. Broderick J., Connolly S., Feldmann E., et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Circulation 116 (2007) e391-e413
3. Brott T., Broderick J., Kothari R., et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 28 (1997) 1-5
4. Mayer S.A. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke 34 (2003) 224-229
5. Davis S.M., Broderick J., Hennerici M., et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66 (2006) 1175-1181
6. Monroe D.M., Hoffman M., Oliver J.A., et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99 (1997) 542-547
7. Hedner U., and Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 1 (2003) 112-119
8. Franchini M. Recombinant factor VIIa: a review on its clinical use. Int J Hematol 83 (2006) 126-138
9. Mariani G., Lapecorella M., and Dolce A. Steps towards an effective treatment strategy in congenital factor VII deficiency. Semin Hematol 43 (2006) S42-S47
10. Arkin S., Cooper H.A., Hutter J.J., et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the NovoSeven emergency-use program. Haemostasis 28 (1998) 93-98
11. Freeman W.D., Brott T.G., Barrett K.M., et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 79 (2004) 1495-1500
12. You H., and Al-Shahi R. Haemostatic drug therapies for acute primary intracerebral haemorrhage. Cochrane Database Syst Rev 3 (2006) CD005951
13. Mayer S.A., Brun N.C., Begtrup K., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352 (2005) 777-785
14. Mayer S.A., Brun N.C., Begtrup K., et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 358 (2008) 2127-2137
15. Bui J.D., Despotis G.D., Trulock E.P., et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 124 (2002) 852-854
16. Van der Planken M.G., Schroyens W., Vertessen F., et al. Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion. Blood Coagul Fibrinolysis 13 (2002) 367-370
17. Pavese P., Bonadona A., Beaubien J., et al. FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anaesth 52 (2005) 26-29
18. Marson F., Farnia A., Callegher L., et al. Use of recombinant activated factor VII (rFVIIa-NovoSeven) in the treatment of uncontrolled postsurgical hemorrhage in a patient with deep venous thrombosis and caval filter. A case report. Minerva Anestesiol 72 (2006) 675-682
19. Chalwin R.P., Tiruvoipati R., and Peek G.J. Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg 34 (2008) 685-686
20. Diringer M.N., Skolnick B.E., Mayer S.A., et al. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 39 (2008) 850-856
21. Biondi-Zoccai G.G., Agostoni P., Abbate A., et al. A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 34 (2005) 224-225
22. Lau J., Ioannidis J.P., and Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 127 (1997) 820-826
23. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
24. Mayer S.A., Brun N.C., Broderick J., et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 36 (2005) 74-79
25. Mayer S.A., Brun N.C., Broderick J., et al. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocrit Care 4 (2006) 206-214
26. Narayan R.K., Maas A.I., Marshall L.F., et al. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery 62 (2008) 776-786 [discussion 86-8]
27. Ruiz-Sandoval J.L., Chiquete E., Romero-Vargas S., et al. Grading scale for prediction of outcome in primary intracerebral hemorrhages. Stroke 38 (2007) 1641-1644
28. Steiner T., Diringer M.N., Schneider D., et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery 59 (2006) 767-773 [discussion 73-4]
29. Mayer S.A., Davis S.M., Skolnick B.E., et al. Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?. Stroke 40 (2009) 833-840
30. Hoffman M., Monroe D.M., and Roberts H.R. Platelet-dependent action of high-dose factor VIIa. Blood 100 (2002) 364-365
31. O'Connell K.A., Wood J.J., Wise R.P., et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006) 293-298
32. Chang E.F., Meeker M., and Holland M.C. Acute traumatic intraparenchymal hemorrhage: risk factors for progression in the early post-injury period. Neurosurgery 61 (2007) 222-230 [discussion 30-1]
33. Oertel M., Kelly D.F., McArthur D., et al. Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg 96 (2002) 109-116
34. Narayan R.K., Maas A.I., Servadei F., et al. Progression of traumatic intracerebral hemorrhage: a prospective observational study. J Neurotrauma 25 (2008) 629-639
35. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 338S-400S
36. Rost N.S., Smith E.E., Chang Y., et al. Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. Stroke 39 (2008) 2304-2309